Androgen receptor: Difference between revisions
From Proteopedia
Jump to navigationJump to search
No edit summary |
No edit summary |
||
| Line 75: | Line 75: | ||
<scene name='89/895670/Cv/6'>Human androgen receptor bound to testosterone</scene> ([[2ylo]]). | <scene name='89/895670/Cv/6'>Human androgen receptor bound to testosterone</scene> ([[2ylo]]). | ||
===Antagonist: Steroid ARA=== | ===Antagonist: Steroid Androgen Receptor Antagonist (ARA)=== | ||
The development of | The development of these drugs were one of the first approaches to treat prostate cancer, targeting AR activity by having a structure with a steroidal skeleton <ref name="ARA prostate" />. | ||
This kind of antiandrogens have another steroid receptor affinity (glucocorticoids receptor, progesterone receptor…) having low efficiency and some side effects like hepatotoxicity and increased cardiovascular risks <ref name="ARA prostate" />. Some examples are cyproterone acetate (CPA) <ref name="ARA prostate" /><ref name="bicalutamide">PMID: 15833816</ref><ref name="nonsteroidal">PMID: 16841196</ref> or megestrol acetate <ref name="ARA prostate" />. | This kind of antiandrogens have another steroid receptor affinity (glucocorticoids receptor, progesterone receptor…) having low efficiency and some side effects like hepatotoxicity and increased cardiovascular risks <ref name="ARA prostate" />. Some examples are cyproterone acetate (CPA) <ref name="ARA prostate" /><ref name="bicalutamide">PMID: 15833816</ref><ref name="nonsteroidal">PMID: 16841196</ref> or megestrol acetate <ref name="ARA prostate" />. | ||
